JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 4
Peculiarities of Radionuclide Diagnosis of Signal Lymph Nodes in Patients of Breast Cancer with Using of Radiopharmaceutical Based on the Gamma-Aluminum Oxide Labeled with 99mTc
A.A. Medvedeva, V.I. Chernov, R.V. Zelchan, O.D. Bragina,
A.N. Rуbina, E.Iu. Garbukov, A.V. Doroshenko,
N.A. Tarabanovskaya
Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia
Contact person: Anna Alexandrovna Medvedeva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To study the possibility of using [99mТс]-Al2O3 for the diagnosis of sentinel lymph nodes (SLN) in patients with breast cancer, to analyze the results obtained in comparison with a phytate colloid labeled with 99mTc.
Material and methods: The study included 86 patients with breast cancer. [99mTc]-phytate colloid (31 patients) and [99mТс]-Al2O3 (55 patients) were used as radiopharmaceutical.
Results: The optimal time interval between the injection of [99mТс]-Al2O3 and the acquisition of a scintigraphic image was determined to be 18-20 hours, when the maximum possible number of lymph nodes (LNs) with the most optimal level of radioactivity for their detection is visualized.
In the group of patients who were injected with [99mTc]-phytate colloid, SLN were visualized in 27 out of 31 patients, a total of 37 LNs were detected in this group. The median number of detected LNs in one patient was 1 [0–3], the intensity of accumulation of [99mTc]-phytate colloid according to single-photon emission computed tomography (SPECT) was 1.75% [0.5–4.3%], intraoperatively using gamma -probe – 2.95% [1.1–5.6%].
When [99mТс]-Al2O3 was used as radiopharmaceutical, SLNs were detected in 51 patients out of 55. In total, 111 LNs were detected in this group, the median number of detected LNs in one patient was 2 [0-6], the intensity of accumulation of [99mТс]-Al2O3 according to SPECT data – 6.1% [0.5–18.4%], intraoperatively – 7.2% [1.3–22.1%].
In the absence of radiopharmaceuticals accumulation in regional LNs (n=7 in total), 3 patients had total metastatic lesions of the SLN, in two of them other regional LNs were also affected by metastases.
Conclusion: A comparative analysis of the indices of two radiopharmaceuticals shows that studies with [99mТс]-Al2O3 are characterized by statistically significantly higher accumulation rates in the SLN compared with [99mTc]-phytate colloid. The number of detected LNs when using [99mТс]-Al2O3 was also higher than in the group with [99mTc]-phytate colloid. As a result, when [99mТс]-Al2O3 is used, the method is characterized by higher sensitivity in detecting SLN (94.5%).
Keywords: 99mТс, gamma alumina, sentinel lymph node, breast cancer
For citation: Medvedeva AA, Chernov VI, Zelchan RV, Bragina OD, Rуbina AN, Garbukov EIu, Doroshenko AV, Tarabanovskaya NA. Peculiarities of Radionuclide Diagnosis of Signal Lymph Nodes in Patients of Breast Cancer with Using of Radiopharmaceutical Based on the Gamma-Aluminum Oxide Labeled with 99mTc. Medical Radiology and Radiation Safety. 2022;67(4):74-79. DOI: 10.33266/1024-6177-2022-67-4-74-79
References
1. Benson J.R., Della Rovere G.Q. Axilla Management Consensus Group. Management of the Axilla in Women with Breast Cancer. Lancet Oncol. 2007;8:331–348.
2. Krag D.N., Anderson S.J., Julian T.B., et al. Sentinel-Lymph-Node Resection Compared with Conventional Axillary-Lymph-Node Dissection in Clinically Node-Negative Patients with Breast Cancer: Overall Survival Findings from the NSABP B-32 Randomised Phase 3 Trial. Lancet Oncol. 2010;11;10:908-909.
3. Moo T.A., Sanford R., Dang C., Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018;13;3:339–354.
4. Plichta J.K. Breast Cancer Prognostic Staging and Internal Mammary Lymph Node Metastases: a Brief Overview. Chin. Clin. Oncol. 2019;8:1–11.
5. Afanasyeva K.V., Petrovskiy A.V., Nechushkin M.I., Shiryayev S.V., et al. Life Quality Assessment in Breast Cancer Patientes after an Axillary Lymph Node Dissection Comparing with a Sentinel Lymph Node Biopsy. Vestnik RONTS im. N. N. Blokhina RAMN = Journal of N. N. Blokhin Russian Cancer Research Center. 2017;28;1–2:45–52 (In Russ.).
6. Krivorotko P.V., Kanayev S.V., Semiglazov V.F., Novikov S.N., et al. Methodological problems of sentinel lymph node biopsy in patients with breast cancer. Voprosy Onkologii = Problems in Oncology. 2015;61;3:418-423 (In Russ.).
7. Vaz S.C., Oliveira F., Herrmann K., Veit-Haibach P. Nuclear Medicine and Molecular Imaging Advances in the 21st Century. Br. J. Radiol. 2020;93;1110:20200095.
8. Chernov V.I., Dudnikova E.A., Zelchan R.V., Kravchuk T.L. et al. The First Experience of Using 99mTc-1-Thio-d-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Siberian Journal of Oncology. 2018;17;4:81-87.
9. Titskaya A.A., Chernov V.I., Slonimskaya Ye.M., Sinilkin I.G. Comparison of 99mTc-MIBI Mammoscintigraphy Findings in Planar and Tomographic Images. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2008;53;5:51-60 (In Russ.).
10. Chernov V.I., Zelchan R.V., Titskaya A.A., Sinilkin I.G., et al. Gamma Scintigraphy with 99mTc-MIBI in the Complex Diagnostics and Assessment of Neoadjuvant Chemotherapy Efficacy in Laryngeal and Laryngopharyngeal Cancers. Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2011;56;2:38-43 (In Russ.).
11. Zavadovskaya V.D., Kurazhov A.P., Kilina O.YU., Choynzonov Ye.L., et al. Differential Diagnostics Inflammatory and Neoplastic Processes of Locomotor Sistem with 199Tl-Сhloride Scintigraphy. Meditsinskaya Vizualizatsiya = Medical Visualization. 2009;4:55-65 (In Russ.).
12. Zhang J.J., Zhang W.C., An C.X., Li X.-M., Ma L. Comparative Research on 99mTc-Rituximab and 99mTc-Sulfur Colloid in Sentinel Lymph Node Imaging of Breast Cancer. BMC Cancer. 2019;1:956.
13. Unkart J.T., Proudfoot J., Wallace A.M. Outcomes of «One-Day» vs «Two-Day» Injection Protocols Using Tc-99m Tilmanocept for Sentinel Lymph Node Biopsy in Breast Cancer. Breast J. 2018;24;4:526–530.
14. Chernov V., Sinilkin I., Choynzonov E., Chijevskaya S. et al. Comparative Evaluation of 99mTс-Al2O3 and 99mTс-Fitat Nanocolloids for Sentinel Lymph Nodes Visualization in Patients with Cancer of Larynx and Hypopharynx. Eur. J. Nucl. Med. Mol. Imaging. 2015;42;S1:704.
15. Sinilkin I., Chernov V., Zelchan R., Titskaya A.A., Skuridin V. Clinical Investigaition of Nanocolloid 99mTс-Al2O3 for Sentinel Lymph Nodes Visualization. Eur. J. Nucl. Med. Mol. Imaging. 2014;41;(Suppl 2):518.
16. Agrawal A, Civantos FJ, Brumund KT, Chepeha DB et al. 99m Tc-Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-Institutional Trial. Ann. Surg. Oncol. 2015;11:3708–3715.
17. Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zelchan R.V., et al. Experience in the Development of Innovative Radiopharmaceuticals at the Tomsk Research Institute of Oncology. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2015;Appendix2:45-47 (In Russ.).
18. Persico M.G., Lodola L., Buroni F.E., Morandotti M., et al. (99m)Tc-Human Serum Albumin Nanocolloids: Particle Sizing and Radioactivity Distribution. J. Labelled Comp. Radiopharm. 2015;58;9:376-382.
19. Yararbas U., Argon A.M., Yeniay L., Zengel B., Kapkaç M. The Effect of Radiocolloid Preference on Major Parameters in Sentinel Lymph Node Biopsy Practice in Breast Cancer. Nucl. Med. Biol. 2010;37;7:805-810.
20. Jimenez I.R., Roca M., Vega E., García M.L., et al. Particle Sizes of Colloids to Be Used in Sentinel Lymph Node Radio Localization. Nucl. Med. Commun. 2008;29;2:166–172.
21. Skuridin V.S., Stasyuk Ye.S., Varlamova N.V., Rogov A.S., et al. Obtaining a new nanocolloidal radiopharmaceutical based on aluminum oxide. Izvestiya Tomskogo Politekhnicheskogo Universiteta. Inzhiniring Georesursov = Bulletin of the Tomsk Polytechnic University. Geo Assets Engineering. 2013;323;3:33–37 (In Russ.).
22. Skuridin V.S., Chernov V.I., Varlamova N.V., Nesterov Ye.A., et al. Study of Functional Fitness Radiopharmaceuticals "Nanocolloids,99mTс-Al2O3" for Scintigraphic and Intraoperative Identification of "Sentinel" Lymph Nodes. Diagnosticheskaya i Interventsionnaya Radiologiya = Diagnostic and Interventional Radiology. 2015. № 3. С. 76–80 (In Russ.).
23. Cheng G., Kurita S., Torigian D.A., Alavi A. Current Status of Sentinel Lymph-Node Biopsy in Patients with Breast Cancer. Eur. J. Nucl. Med. Mol. Imaging. 2011;38:562-575.
24. Kanayev S.V., Novikov S.N., Krivorotko P.V., Semiglazov V.F., et al. Methodological Issues of Sentinel Lymph Nodes Biopsy in Patients with Breast Cancer. Voprosy onkologii = Problems in Oncology. 2013. Т.59, № 2. С. 90-94 (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 11.04.2022. Accepted for publication: 11.05.2022